Cargando…

ABT-737, a Bcl-2 Selective Inhibitor, and Chloroquine Synergistically Kill Renal Cancer Cells

Renal cell carcinoma (RCC) is the most common malignancy in the kidney in the world, and the 5-year overall survival for patients remains poor due to the lack of effective treatment strategies. Although ABT-737, as a Bcl-2/Bcl-xL inhibitor, has recently emerged as a novel cancer therapeutic reagent,...

Descripción completa

Detalles Bibliográficos
Autores principales: Yin, Pei, Jia, Jinpeng, Li, Jijun, Song, Yan, Zhang, Yiyan, Chen, Fengkun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cognizant Communication Corporation 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7838628/
https://www.ncbi.nlm.nih.gov/pubmed/27178823
http://dx.doi.org/10.3727/096504016X14587366983838